Company News

Working with cancer patients gave this doctor the perspective and drive to work toward giving them the right tools for the fight.
 

The cystic fibrosis (CF) combination therapy we are developing with Galapagos is on track. Following successful completion of Phase 2 development, AbbVie will be responsible for Phase 3.
 

Less memorization and more hands-on experience – often involving life-science pros – are making science, technology, engineering and math (STEM) more appealing, especially in underserved communities.

Cambridge, Mass. & North Chicago, Ill. –April 29, 2016 –The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has adopted a positive opinion recommending the granting of a marketing authorization for ZINBRYTA™ (daclizumab) intended for the treatment of relapsing forms of multiple sclerosis (RMS), Biogen (NASDAQ: BIIB) and AbbVie (NYSE: ABBV) announced today. ZINBRYTA is a once-monthly, self-administered, subcutaneous investigational treatment for RMS. ZINBRYTA is also currently under regulatory review in the United States, Switzerland, Canada and Australia.
 

An increased understanding of tumor biology allows researchers to explore new ways to target cancer cells by combining toxins with antibodies.
 

We believe 2016 is off to an exceptional start, with double-digit sales and adjusted earnings growth in the first quarter. Read the full news release.

Redirect

It sometimes takes a scientist who is also a curious sleuth to pinpoint a virus. Wondering about the “imperfect logic” of life science led Yao on a 17-year journey from validating drug targets and discovering clinical candidates to developing novel therapies.

A desire to tackle the complex challenge of discovering new drugs for patients has fueled a 31-year career with many contributions to cancer research.

World Parkinson’s Day is observed annually on April 11 to raise awareness of the disease, promoting a greater understanding of the condition and how it can affect a person. Learn more about the disease, how many people are impacted, treatment and more.